L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-tieulent et al., Global cancer statistics, CA Cancer J Clin, vol.65, pp.87-108, 2012.

R. Labianca, B. Nordlinger, G. D. Beretta, S. Mosconi, M. Mandala et al., Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.24, pp.64-72, 2013.

T. Andre, C. Boni, M. Navarro, J. Tabernero, T. Hickish et al., Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial, J Clin Oncol, vol.27, pp.3109-3116, 2009.

J. P. Kuebler, H. S. Wieand, M. J. O'connell, R. E. Smith, L. H. Colangelo et al.,

M. P. Petrelli, T. E. Findlay, J. N. Seay, J. L. Atkins, J. W. Zapas et al., Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07, J Clin Oncol, vol.25, pp.2198-2204, 2007.

S. R. Alberts, D. J. Sargent, S. Nair, M. R. Mahoney, M. Mooney et al., Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial, JAMA, vol.307, pp.1383-1393, 2012.

C. J. Allegra, G. Yothers, M. J. O'connell, S. Sharif, N. J. Petrelli et al.,

. Wolmark, Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08, J Clin Oncol, vol.29, pp.11-16, 2011.

J. Taieb, J. Tabernero, E. Mini, F. Subtil, G. Folprecht et al.,

L. N. Bridgewater, H. Petersen, L. Blons, E. Collette, P. Van-cutsem et al.,

J. F. Bedenne, P. Emile, C. Laurent-puig, P. Lepage, and . Investigators, Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III
URL : https://hal.archives-ouvertes.fr/hal-02045524

, PETACC-8): an open-label, randomised phase 3 trial, Lancet Oncol, vol.15, pp.862-873, 2014.

H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth et al., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, vol.350, pp.2335-2342, 2004.

E. Van-cutsem, C. H. Kohne, E. Hitre, J. Zaluski, C. R. Chang-chien et al.,

T. D'haens, R. Pinter, G. Lim, J. K. Bodoky, G. Roh et al.,

J. Schlichting, P. Nippgen, and . Rougier, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer, N Engl J Med, vol.360, pp.1408-1417, 2009.

F. Cappuzzo, M. Varella-garcia, G. Finocchiaro, M. Skokan, S. Gajapathy et al.,

E. Rimassa, C. Rossi, L. D. Ligorio, A. J. Tommaso, L. Holmes et al., Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients, Br J Cancer, vol.99, pp.83-89, 2008.

J. Codony-servat, M. Cuatrecasas, E. Asensio, C. Montironi, A. Martinez-cardus et al.,

J. Mendez, A. Gallego, F. Salud, A. Rojo, A. Castells et al., Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer, Br J Cancer, vol.117, pp.1777-1786, 2017.

G. P. Ewing and L. W. Goff, The insulin-like growth factor signaling pathway as a target for treatment of colorectal carcinoma, Clin Colorectal Cancer, vol.9, pp.219-223, 2010.

A. Hakam, T. J. Yeatman, L. Lu, L. Mora, G. Marcet et al., Expression of insulin-like growth factor-1 receptor in human colorectal cancer, Hum Pathol, vol.30, pp.1128-1133, 1999.

L. Han, G. F. Zhang, Y. H. Cheng, and Q. C. Zhao, Correlations of insulin-like growth factor I and insulin-like growth factor I receptor with the clinicopathological features and prognosis of patients with colon cancer, Jpn J Clin Oncol, vol.46, p.19, 2016.

F. Huang, L. A. Xu, and S. Khambata-ford, Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer, Clin Cancer Res, vol.18, pp.1156-1166, 2012.

A. Inno, M. D. Salvatore, T. Cenci, M. Martini, A. Orlandi et al., Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer, Clin Colorectal Cancer, vol.10, pp.325-332, 2011.

M. Nakamura, S. Miyamoto, H. Maeda, S. C. Zhang, T. Sangai et al., Low levels of insulin-like growth factor type 1 receptor expression at cancer cell membrane predict liver metastasis in Dukes' C human colorectal cancers, Clin Cancer Res, vol.10, pp.8434-8441, 2004.

G. Peters, S. Gongoll, C. Langner, M. Mengel, P. Piso et al., IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer, Virchows Arch, vol.443, pp.139-145, 2003.

F. Sclafani, T. Y. Kim, D. Cunningham, T. W. Kim, J. Tabernero et al.,

Y. S. Kim, T. K. Park, E. Guren, S. J. Hawkes, D. Clarke et al., A randomized phase II/III study of dalotuzumab in combination with cetuximab and irinotecan in chemorefractory, KRAS wild-type, metastatic colorectal cancer, J Natl Cancer Inst, vol.107, p.258, 2015.

I. Shiratsuchi, Y. Akagi, A. Kawahara, T. Kinugasa, K. Romeo et al., Expression of IGF-1 and IGF-1R and their relation to clinicopathological factors in colorectal cancer, Anticancer Res, vol.31, pp.2541-2545, 2011.

D. Takahari, Y. Yamada, N. T. Okita, T. Honda, Y. Hirashima et al., Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer, Oncology, vol.76, pp.42-48, 2009.

C. Zhang, L. Hao, L. Wang, Y. Xiao, H. Ge et al., Elevated IGFIR expression regulating VEGF and VEGF-C predicts lymph node metastasis in human colorectal cancer, BMC Cancer, vol.10, p.20, 2010.

L. Zhang, W. Zhou, V. E. Velculescu, S. E. Kern, R. H. Hruban et al., Gene expression profiles in normal and cancer cells, Science, vol.276, pp.1268-1272, 1997.

D. Leroith, C. T. Roberts, and J. , The insulin-like growth factor system and cancer, Cancer Lett, vol.195, pp.127-137, 2003.

D. L. Reidy, E. Vakiani, M. G. Fakih, M. W. Saif, J. R. Hecht et al., Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab-or panitumumab-refractory metastatic colorectal cancer, J Clin Oncol, vol.28, pp.4240-4246, 2010.

J. Tabernero, S. P. Chawla, H. Kindler, K. Reckamp, E. G. Chiorean et al., Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab, Target Oncol, vol.10, pp.65-76, 2015.

E. Van-cutsem, C. Eng, E. Nowara, A. Swieboda-sadlej, N. C. Tebbutt et al.,

J. Davidenko, E. Stephenson, H. Elez, H. Prenen, R. Deng et al., Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer, Clin Cancer Res, vol.20, pp.4240-4250, 2014.

R. Liu, L. L. Hu, A. Sun, Y. J. Cao, T. Tang et al., mRNA expression of IGF-1 and IGF-1R in patients with colorectal adenocarcinoma and type 2 diabetes, Arch Med Res, vol.45, pp.318-324, 2014.

A. Zaanan, P. Cuilliere-dartigues, A. Guilloux, Y. Parc, C. Louvet et al.,

B. Dumont, P. Gayet, J. F. Validire, A. Flejou, F. Duval et al., Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin, Ann Oncol, vol.21, pp.772-780, 2010.

A. Zaanan, J. F. Flejou, J. F. Emile, G. G. Des, P. Cuilliere-dartigues et al.,

C. Validire, P. Louvet, A. Rougier, F. De-gramont, F. Bonnetain et al., Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon ! 21 cancer patients treated with adjuvant FOLFOX chemotherapy, Clin Cancer Res, vol.17, pp.7470-7478, 2011.

H. Blons, J. F. Emile, K. L. Malicot, C. Julié, A. Zaanan et al.,

M. A. Lepage, R. Zawadi, P. Salazar, J. Laurent-puig, and . Taieb, Prognostic value of KRAS mutations in stage III colon cancer : post hoc analysis of the PETACC8 phase III trial dataset

, Ann Oncol, vol.25, pp.2378-2385, 2014.

C. M. Ribic, D. J. Sargent, M. J. Moore, S. N. Thibodeau, A. J. French et al.,

P. Hamilton, R. Laurent-puig, L. E. Gryfe, D. Shepherd, M. Tu et al., Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer, N Engl J Med, vol.349, pp.247-257, 2003.

D. J. Sargent, S. Marsoni, G. Monges, S. N. Thibodeau, R. Labianca et al., Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer, J Clin Oncol, vol.28, pp.3219-3226, 2010.

P. G. Gavin, L. H. Colangelo, D. Fumagalli, N. Tanaka, M. Y. Remillard et al.,

S. I. Taniyama, H. J. Kim, N. L. Choi, C. Blackmon, N. J. Lipchik et al.,

S. Wolmark, K. L. Paik, and . Pogue-geile, Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value, Clin Cancer Res, vol.18, pp.6531-6541, 2012.

A. Zaanan, Q. Shi, J. Taieb, S. R. Alberts, J. P. Meyers et al.,

P. Sargent, F. A. Laurent-puig, and . Sinicrope, Role of deficient DNA mismatch repair status in patients with stage III colon cancer treated with FOLFOX adjuvant chemotherapy: a pooled analysis from 2 randomized clinical trials, JAMA Oncol, vol.4, pp.379-383, 2018.

A. Zaanan, J. B. Bachet, T. André, and F. A. Sinicrope, Prognostic impact of deficient DNA mismatch repair and mutations in KRAS, and BRAF(V600E) in patients with lymph nodepositive colon cancer, Curr Colorectal Cancer Rep, vol.10, p.22, 2014.

J. Taieb, A. Zaanan, K. L. Malicot, K. , C. Julie et al.,

, Prognostic effect of BRAF and KRAS mutations in patients with stage III colon cancer treated with leucovorin, fluorouracil, and oxaliplatin with or without cetuximab: a post hoc analysis of the PETACC-8 trial, JAMA Oncol, vol.14, pp.1-11, 2016.

R. Dienstmann, M. J. Mason, F. A. Sinicrope, A. I. Phipps, S. Tejpar et al.,

R. A. Milburn-jessup, M. Lothe, P. A. Delorenzi, D. Newcomb, J. Sargent et al., Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study, Ann Oncol, vol.28, pp.1023-1031, 2017.

J. Taieb, K. L. Malicot, Q. Shi, F. Lorca, O. Bouche et al.,

L. Puig and F. A. Sinicrope, Prognostic value of BRAF and KRAS mutations in MSI and MSS stage III colon cancer, J Natl Cancer Inst, vol.109, 2017.

B. Ducos, S. Cabrol, M. Houang, L. Perin, M. Holzenberger et al., IGF type 1 receptor ligand binding characteristics are altered in a subgroup of children with intrauterine growth retardation, J Clin Endocrinol Metab, vol.86, pp.5516-5524, 2001.

N. Hizuka, K. Takano, I. Tanaka, N. Honda, T. Tsushima et al., Characterization of insulin-like growth factor I receptor on human erythrocytes, J Clin Endocrinol Metab, vol.61, pp.1066-1070, 1985.

K. Kawamoto, H. Onodera, S. Kondo, S. Kan, D. Ikeuchi et al., Expression of insulin-like growth factor-2 can predict the prognosis of human colorectal cancer patients: correlation with tumor progression, proliferative activity and survival, Oncology, vol.55, pp.242-248, 1998.

C. Barozzi, M. Ravaioli, A. Errico, G. L. Grazi, G. Poggioli et al.,

. Grigioni, Relevance of biologic markers in colorectal carcinoma: a comparative study of a broad panel, Cancer, vol.94, pp.647-657, 2002.